Welcome to ERS Genomics’ CRISPR/Cas9 Licensing Platform
Accessing cutting-edge genetic research tools shouldn’t be an uphill battle for startups. That’s why ERS Genomics, armed with the pioneering patent rights of Nobel Laureate Emmanuelle Charpentier, aims to simplify and expedite the process of acquiring CRISPR/Cas9 licenses. Our platform is designed to offer startups affordable and swift access to this groundbreaking technology for internal research purposes.
Facilitating Access to Genetic Innovation
We understand the challenges startups face when it comes to adopting transformative technologies. Our click license platform ensures startups can swiftly obtain CRISPR/Cas9 licenses at a fixed yearly fee, enabling immediate access to fundamental patent rights. By simplifying the licensing procedure, we eliminate unnecessary barriers, allowing startups to explore the potential of CRISPR/Cas9 without complex bureaucratic hurdles.
For startups keen on delving into genetic innovation, our program offers an accessible pathway. The program provides access to CRISPR/Cas9 licensing at a yearly fee of $15,000, ensuring startups can explore the potential of this revolutionary technology without financial strain or prolonged delays.